News
Current News
- First myeloma kidney patient recruited onto EuLITE clinical trial09 June 2008
- Biennial 2008 - Serum Free Light Chain Symposium14 May 2008
- New Cystatin C assay for Roche Modular P18 March 2008
- Independent Review discusses Value of Serum Free Light Chain Assays11 February 2008
- Serum FLC ratio can help assess risk in patients with Smouldering Multiple Myeloma24 January 2008
- Serum free light chain assay recommended in initial investigation of myeloma19 October 2007
09 June 2008
First myeloma kidney patient recruited onto EuLITE clinical trial
Binding Site announces the launch of a new clinical trial for patients suffering from myeloma kidney with the recruitment of the first patient onto the EuLITE trial.
EuLITE is a randomised control trial being carried out across a number of British and German Acute nephrology units. It combines use of Freelite™ to monitor levels of nephrotoxic free light chains in serum, light chain removal using a high cut off haemodialysis filter (HCO1100, Gambro) and tumour kill with Velcade-based chemotherapy, with the aim of restoring renal function in patients with myeloma kidney.
EuLITE is based on a pilot study conducted at the Queen Elizabeth Hospital, Birmingham. Renal function was restored in over 70% of myeloma patients treated with high cut off haemodialysis and chemotherapy. This represents a significant improvement over historical controls in which only 11% became dialysis-independent. Restoring renal function in myeloma patients is associated with an increase in life expectancy from 6 months to several years and dramatic gains in quality of life.
Commenting on today's announcement, Paul Duncan, Chief Executive Officer of Binding Site, said:
"I am delighted to announce the recruitment of the first patient for the new EuLITE trial. The availability of Freelite for measuring serum levels of immunoglobulin free light chains in myeloma patients has allowed the accurate assessment of removal therapies for the first time. It is hoped that combined with high cut-off haemodialysis and efficacious chemotherapy the management of myeloma kidney patients and their future outcome can be significantly improved."
Review the clinical evidence for Freelite serum free light chains or contact us for further information.
